Last reviewed · How we verify
Part2: COVID-19 Vaccine, mRNA — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Part2: COVID-19 Vaccine, mRNA (Part2: COVID-19 Vaccine, mRNA) — Jiangsu Rec-Biotechnology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Part2: COVID-19 Vaccine, mRNA TARGET | Part2: COVID-19 Vaccine, mRNA | Jiangsu Rec-Biotechnology Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Part2: COVID-19 Vaccine, mRNA CI watch — RSS
- Part2: COVID-19 Vaccine, mRNA CI watch — Atom
- Part2: COVID-19 Vaccine, mRNA CI watch — JSON
- Part2: COVID-19 Vaccine, mRNA alone — RSS
Cite this brief
Drug Landscape (2026). Part2: COVID-19 Vaccine, mRNA — Competitive Intelligence Brief. https://druglandscape.com/ci/part2-covid-19-vaccine-mrna. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab